Results for this period
Full year1 April 2025–31 March 2026ConsolidatedIFRSThe width of the band at each stage is based on revenue. The narrower it becomes toward the bottom, the smaller the proportion of revenue that remains as profit. The dotted outline is the full-year forecast and the band inside it is the result for this period. The progress rate is the result divided by the forecast.
塗りつぶした部分が自己資本比率です。総資産のうち、返済のいらない自前の資金がどれだけかを表します。The thin vertical line indicates the level at the end of the previous fiscal year.
Stacked from zero: upward is an increase in cash, downward a decrease (in Millions of yen).The net change represented by the dotted line is the total of three items, calculated from figures provided by the company.
In the current fiscal year, the company classified its U.S. business as a discontinued operation, and profit for the period from discontinued operations declined from ¥9,796 million in the previous fiscal year to a loss of ¥1,098 million in the current fiscal year. In the next fiscal year, profitability is expected to improve as a result of higher minimum drug prices and the launch of new products, while costs are expected to increase due to soaring energy prices, inflation and the weaker yen.
None. The notes regarding the going concern assumption state, “There are no applicable matters.”
| Item | Details |
|---|---|
| Fiscal Period Classification | Full year |
| Accounting standards | IFRS |
| Consolidated / non-consolidated | Consolidated |
| Period Covered | 1 April 2025–31 March 2026 |
| Net Sales | 201,676 Millions of yen (YoY +6.7%) |
| Operating profit | 15,894 Millions of yen (YoY +292.5%) |
| Ordinary income | 14,273 Millions of yen (YoY +351.5%) |
| Profit attributable to owners of the parent | 10,438 Millions of yen (YoY -12.8%) |
| Net income per share | ¥90.39 |
| Operating Margin | 7.9% |
| Equity ratio | End of the current fiscal period 49.6% / End of previous period 49.0% |
| Total assets | 359,919 Millions of yen |
| Net assets | 178,556 Millions of yen |
| Cash flows from operating activities | 7,433 Millions of yen |
| Cash flows from investing activities | -22,898 Millions of yen |
| Cash flows from financing activities | 5,587 Millions of yen |
| Cash and cash equivalents at end of period | 28,989 Millions of yen |
| Full-year earnings forecast | Net Sales 208,400 Millions of yen (YoY +3.3%) / Operating profit 27,200 Millions of yen (YoY +71.1%) / Ordinary income 26,000 Millions of yen (YoY +82.2%) / Net income 18,600 Millions of yen (YoY +78.2%) |
| Annual Dividend Forecast | ¥55 → ¥56（+1.8%） |
| Payout ratio | 34.8% |
| Depreciation and amortization | 16,002 Millions of yen |
| Impairment loss | 1,736 Millions of yen |
| Disclosure regarding the going concern assumption | None. The notes regarding the going concern assumption state, “There are no applicable matters.” |
| Change in accounting policy | Changes due to revisions to standards No / Other changes No / Change in accounting estimate No / Restatement Not disclosed |
| Changes in the scope of consolidation | New 1 / Name of newly added company FrontAct株式会社 / Excluded 0 / Excluded Company Name Not disclosed |
| Availability of Supplementary Financial Results Materials | Yes |
| Availability of Financial Results Briefing | Available (for institutional investors and analysts) |
| Issued Shares at Period-End | 115,487,137 |
| Treasury Shares at Period-End | 1,503 |
| Factors Behind Changes in Business Performance | In the current fiscal year, the company classified its U.S. business as a discontinued operation, and profit for the period from discontinued operations declined from ¥9,796 million in the previous fiscal year to a loss of ¥1,098 million in the current fiscal year. In the next fiscal year, profitability is expected to improve as a result of higher minimum drug prices and the launch of new products, while costs are expected to increase due to soaring energy prices, inflation and the weaker yen. |
Items this document does not state (8)
These are items the company does not state in this document. We do not leave them blank, nor fill them in from other sources or by inference.
The reasons the company gives
The company's own explanation, not something inferred from the numbers.The company has classified its U.S. business as a discontinued operation and explained that profit for the period from discontinued operations declined from ¥9,796 million in the previous fiscal year to a loss of ¥1,098 million in the current fiscal year. For the fiscal year ending March 2027, the company expects profitability to improve as a result of higher minimum drug prices and the launch of new products, while also anticipating higher costs due to soaring energy prices, inflation and the weaker yen.